glp 1 drugs for alcohol use disorder GLP-1 plus therapy can reduce heavy drinking GLP-1 Anti-Obesity Rx and Alcohol

Insulin in the brain: there and back again

HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists

When examining a composite cardio outcomes endpoint (death from CV disease, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina), the ELIXA trial suggested that GLP-1s did not increase cardiovascular event risk (hazard ratio of 1.02)

Identification of incident pancreatic cancer in Ontario administrative health data: a validation study

Stay well-hydrated , particularly if you experience gastrointestinal side effects

Possible increased risk of gallbladder or biliary disorders, especially with long-term use